U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer
Bristol-Myers Squibb Company announced that Opdivo (nivolumab) received approval from the U.S. FDA as the first and only Immuno-Oncology treatment option for patients with...
Healthy Interactions and Merck announce launch of digital health platform designed to enhance patient engagement in diabetes management
Healthy Interactions, a global leader in health education, in collaboration with Merck , known as MSD outside the United States and Canada, announced the...
Eisai And Merck announce FDA approval of LENVIMA capsules for first-line treatment of Unresectable Hepatocellular Carcinoma
Eisai Inc. and Merck , known as MSD outside of the United States and Canada , announced that the U.S. FDA approved the kinase...
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases
Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment...
Large Pharmaceutical Company in China Selects TrialMaster® EDC and Acuity Analytics for Major Clinical Study
In a milestone transaction, a major pharmaceutical company based in China will undertake a multisite clinical study using TrialMaster EDC Suite and Acuity Analytics,...
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, announced that it has entered...
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...